NSE: ACUTAAS · 27 October 2026
- Acutaas Chemicals has risen 21.20% over 2 trading sessions; today's move is +13.56%.
- Acutaas Chemicals reported consolidated revenue of ₹4,369 million for the second quarter ended September 30, 2026, marking a 42.7% increase year-on-year. Net profit (PAT) surged 71.4% to ₹1,231 million, driven by gross margins of 62.1% and robust performance in the pharmaceutical intermediates segment. Concurrently, management raised its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%.
- Trading volume was 11.38 times the 20-day average daily volume.
Acutaas Chemicals share price: 21.20% rise over 2 trading sessions
Acutaas Chemicals Ltd. shares surged 13.56% on Tuesday, trading near the top of their intra-day range. The stock opened at ₹3,370.00 and climbed to a day's high of ₹3,900.00, which also marks its new 52-week high, against a low of ₹3,365.20.
The broader market exhibited muted movement, with the benchmark Nifty slipping 0.02%, while the sector benchmark Nifty Metal edged up 0.39%. Acutaas Chemicals significantly outperformed both the broader market and its sector peers, building on its recent momentum that includes a 5-day return of 16.89% and a 20-day return of 16.21%.
The sharp upward move coincides with the release of the company's financial results for the second quarter and half year ended September 30, 2026, filed on October 27, 2026. Management reported consolidated revenue from operations at ₹4,369 million, up 42.7% year-on-year, alongside a PAT of ₹1,231 million, marking a 71.4% increase from the corresponding quarter of the previous year. Furthermore, management revised its FY27 revenue growth guidance upward from 25% to around 30% and raised its EBITDA margin guidance to the 38-40% range, bolstered by the early inauguration of its South Korea semiconductor materials manufacturing facility.
44.40 lakh shares traded by 27 October 2026 · 02:55 PM IST. This compares with a 20-day average daily volume of 3.90 lakh shares (11.38 times). The five-day average daily volume was 5.53 lakh shares. Separately, the NSE report for 26 October 2026 showed 6.51 lakh shares delivered, representing 52.28% of that day’s traded volume. The same report recorded 122,327 trades.
The stock's sharp 13.56% rally to a new 52-week high is strongly supported by the release of Q2 FY27 financial results showing robust year-on-year growth in revenue and profit, alongside an upward revision in annual revenue and EBITDA margin guidance.
Latest Company Developments
Acutaas Chemicals reported consolidated revenue of ₹4,369 million for the second quarter ended September 30, 2026, marking a 42.7% increase year-on-year. Net profit (PAT) surged 71.4% to ₹1,231 million, driven by gross margins of 62.1% and robust performance in the pharmaceutical intermediates segment. Concurrently, management raised its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%.
Strong top-line and bottom-line expansion, coupled with an upward revision in forward guidance, directly influences valuation and investor sentiment.
The company announced the early inauguration of its manufacturing facility in South Korea during the quarter. The plant is equipped to produce high-purity chemicals utilized in photoresists, semiconductor packaging materials, and etching applications.
Expands the company's footprint into the high-growth semiconductor ecosystem and diversifies its revenue streams beyond core pharmaceuticals.
Acutaas Chemicals completed the acquisition of 100% of the equity share capital of Enchem Ami Organics Private Limited through the transfer of shares from its existing subsidiary, making it a direct wholly-owned subsidiary.
Consolidates ownership structure within the group's emerging electrolyte and battery materials business verticals.
Acutaas Chemicals Limited has informed the Exchange that Record date for the purpose of Dividend is 17-Sep-2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.44% on 30 September 2026. This compares with 14.17% on 30 June 2026, a change of +0.27 percentage points.
The filing reported 32 MF/UTI holders.
What to Watch Next
- Execution of the revised FY27 revenue growth guidance of around 30%
- Ramp-up and commercial production progress at the newly inaugurated South Korea semiconductor materials facility
- Performance trends in the specialty chemicals segment alongside ongoing momentum in pharmaceutical intermediates
- Sustained delivery volumes and institutional participation levels above the 20-day average volume
Other Dated Coverage
- Acutaas Chemicals Share Price Today: Why ACUTAAS Is Rising 6.73% | 26 October 2026 — 26 October 2026
More Acutaas Chemicals news and dated analysis →
Frequently Asked Questions
What is the latest Acutaas Chemicals company news?
Acutaas Chemicals reported consolidated revenue of ₹4,369 million for the second quarter ended September 30, 2026, marking a 42.7% increase year-on-year. Net profit (PAT) surged 71.4% to ₹1,231 million, driven by gross margins of 62.1% and robust performance in the pharmaceutical intermediates segment. Concurrently, management raised its FY27 revenue growth guidance to around 30% and EBITDA margin guidance to 38-40%.
How strong was Acutaas Chemicals’s trading volume?
44.40 lakh shares traded, 11.38 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 · 02:55 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.